Real life use of natalizumab, fingolimod, dimethylfumarate, teriflunomide and alemtuzumab in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

被引:0
|
作者
Guger, M. [1 ]
Enzinger, C. [2 ]
Leutmezer, F. [3 ]
Kraus, J. [4 ]
Berger, T. [5 ]
机构
[1] Kepler Univ Clin, Clin Neurol 2, Med Campus 3, Linz, Austria
[2] Med Univ Graz, Dept Neurol, Graz, Austria
[3] Med Univ Vienna, Dept Neurol, Vienna, Austria
[4] Publ Hosp Zell Am See, Dept Neurol, Zell Am See, Austria
[5] Med Univ Innsbruck, Dept Clin Neurol, Innsbruck, Austria
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
EP1510
引用
收藏
页码:788 / 789
页数:2
相关论文
共 50 条
  • [12] A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy
    Walker, Anna
    Watson, Crystal
    Alexopoulos, Stamatia T.
    Deniz, Baris
    Arnold, Ryan
    Bates, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 629 - 635
  • [13] Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria
    Walter, Evelyn
    Berger, Thomas
    Bajer-Kornek, Barbara
    Deisenhammer, Florian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 226 - 237
  • [14] Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey
    Terzi, M.
    Kurtuncu, M.
    Eraksoy, M.
    Karabudak, R.
    Tuncer, A.
    Altunrende, B.
    Akcali, A.
    Boz, C.
    Sevim, S.
    Nur, Y.
    Tamam, Y.
    Bitnel, M.
    Turan, O. F.
    Soysal, A.
    Ozerden, M.
    Terzi, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 310 - 310
  • [15] Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab-A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
    Guger, Michael
    Traxler, Gerhard
    Drabauer, Martina
    Leitner-Pohn, Doris
    Enzinger, Christian
    Leutmezer, Fritz
    Oel, Dierk
    Di Pauli, Franziska
    Berger, Thomas
    Ransmayr, Gerhard
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [16] Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Di Pauli, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 629 - 630
  • [17] Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2021, 268 (11) : 4303 - 4310
  • [18] Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Michael Guger
    Christian Enzinger
    Fritz Leutmezer
    Franziska Di Pauli
    Jörg Kraus
    Stefan Kalcher
    Erich Kvas
    Thomas Berger
    Journal of Neurology, 2021, 268 : 4303 - 4310
  • [19] Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data
    Noteboom, S.
    Strijbis, E. M. M.
    Coerver, E. M. E.
    Colato, E.
    van Kempen, Z. L. E.
    Jasperse, B.
    Vrenken, H.
    Killestein, J.
    Schoonheim, M. M.
    Steenwijk, M. D.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 87
  • [20] Real-world safety and effectiveness of natalizumab treatment in patients with relapsing-remitting multiple sclerosis: data from an Irish registry
    McGuigan, C.
    Kinirons, P.
    Ryan, A.
    Moore, H.
    Murphy, S. M.
    Hennessy, M.
    Gibson, B.
    Hayden, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 299 - 300